Volvo Group and Daimler Truck launch Coretura - a Joint Venture to unlock the digital future of commercial vehicles
Following the binding joint venture agreements signed on October 28, 2024, Volvo Group and Daimler Truck have obtained all required regulatory approvals and have now launched the new company Coretura. Following the joint venture transaction, Coretura, based in Gothenburg, Sweden, began operations in the beginning of June 2025.
Karin Rådström, President and CEO of Daimler Truck: "With Coretura, we are setting a clear strategic focus on software development for commercial vehicles. This is a big and really exciting step — not just for us, but for the entire industry and our customers. Together we are starting the digital-driven future of trucks and buses, ultimately making commercial vehicles smarter, more connected, and more efficient than ever before."
Martin Lundstedt, President and CEO of the Volvo Group, adds: "Coretura represents a bold step forward in the evolution of commercial vehicles. By leveraging cutting-edge technology and collaborative innovation, we're setting the stage for a new era of connectivity and efficiency in the industry. This venture underscores our commitment to not only advancing our products but also paving the way for sustainable and intelligent transportation solutions."
Coretura will be led by a four-member Executive Management team consisting of two members from each of the shareholders. Johan Lundén has been appointed as CEO coming from Volvo Group where he previously held responsibility for Strategic Product Planning, Project and Innovation management.
Unlocking the digital future of commercial vehicles
As commercial vehicles are becoming more digital, the mission of Coretura is to build the non-differentiating core, a standardized and open software-defined vehicle platform and dedicated commercial vehicle operating system.
Coretura's activities also include the specification and procurement of centralized high-performance control units dedicated for commercial vehicles and capable of handling large amounts of data. This will decouple software and hardware development cycles, allowing end customers to purchase and update digital applications wirelessly 'over the air,' enhancing safety, efficiency and customer experience.
"This joint venture blends the agility of a start-up with the stability and expertise of our major shareholders. We are proud and energized to lead the digital transformation in the commercial vehicle industry—backed by strong shareholder support and committed to shaping the industry's future." says Johan Lundén, CEO of Coretura.
Starting with around 50 employees, Coretura is set to grow stepwise. This allows the shareholders to pool resources and invest in accordance with technical progress and achievement of milestones. Coretura thereby follows a collaborative co-development approach with its customers, aiming to launch its first products in vehicles by the end of the decade.
Volvo Group and Daimler Truck will remain competitors and continue to differentiate their range of product and services offerings, including their respective digital solutions.
Coretura is open to cooperation and invites new and traditional suppliers and partners who share its values to join in creating the future of the industry.
June 17, 2025
Contact Volvo Group:Claes Eliasson, +46 76 553 7229, press@volvo.com Contact Daimler Truck:Paul Mandaiker, +49 176 30999267, paul.mandaiker@daimlertruck.com
For more information, please visit volvogroup.com For frequent updates, follow us on LinkedIn
The Volvo Group drives prosperity through transport and infrastructure solutions, offering trucks, buses, construction equipment, power solutions for marine and industrial applications, financing and services that increase our customers' uptime and productivity. Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions. The Volvo Group is headquartered in Gothenburg, Sweden, employs more than 100,000 people and serves customers in almost 190 markets. In 2024, net sales amounted to SEK 527 billion (EUR 46 billion). Volvo shares are listed on Nasdaq Stockholm.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/ab-volvo/r/volvo-group-and-daimler-truck-launch-coretura---a-joint-venture-to-unlock-the-digital-future-of-comm,c4164958
The following files are available for download:
https://mb.cision.com/Main/39/4164958/3507925.pdf
Press release - Volvo Group and Daimler Truck launch Coretura - a Joint Venture to unlock the digital future of commercial vehicles
https://news.cision.com/ab-volvo/i/250617-volvo-group-coretura,c3419375
250617-volvo-group-coretura
View original content:https://www.prnewswire.com/news-releases/volvo-group-and-daimler-truck-launch-coretura---a-joint-venture-to-unlock-the-digital-future-of-commercial-vehicles-302483493.html
SOURCE AB Volvo
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
5 hours ago
- Bloomberg
Sweden Now Expects Faster Growth in 2026 as Trade Concerns Fade
Sweden's government raised its projection for economic growth next year, saying reduced uncertainty over US tariffs should allow households to begin consuming more over the coming months. 'I am still concerned about tariffs, but at least now we know roughly what level they will be,' Finance Minister Elisabeth Svantesson told reporters in Stockholm on Wednesday. 'Uncertainty has declined in that area.'
Yahoo
5 hours ago
- Yahoo
NCC secures contract to expand Bålforsen hydropower plant in Sweden
NCC has received a contract from energy company Uniper to expand the Bålforsen hydropower plant in Lycksele, Sweden. This project involves installing a new turbine to increase the plant's capacity and efficiency. The order carries a value of around Skr200m ($20m). The project is part of Uniper's plans to increase its supply of renewable energy. Uniper Umeälven expansion project programme manager Jonny Arrehag: 'The Umeälven expansion is an important project as it is fully aligned with our strategy to expand our supply of flexible, green energy.' NCC has been carrying out preparatory work at the facility since late last year. It has now been tasked with installing a new turbine and upgrading existing ones to improve water flow in the river, boost electricity generation, and enhance the delivery of system services. NCC Infrastructure area manager André Persson said: 'Thanks to NCC's extensive experience of advanced infrastructure projects and our strong local connection, we can support Uniper in achieving its goals for the expansion of the Bålforsen hydropower plant. 'This work requires a high level of specialist expertise, and we will maintain a strict focus on safety during the project.' Upon completion, the Bålforsen plant will produce 506GWh annually, meeting the electricity needs of almost 25,000 homes. The Bålforsen hydropower plant project is scheduled for completion in late 2027. The contract's value will be registered by the NCC Infrastructure business segment in the third quarter of 2025. Recently, NCC secured a major contract to provide 200,000 tons of asphalt for the E6 Berkåk-Vindåsliene road development in Norway's Trøndelag region. "NCC secures contract to expand Bålforsen hydropower plant in Sweden" was originally created and published by World Construction Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Alligator Bioscience Provides Highlights from R&D Event 2025
LUND, SE / / August 20, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, provides key highlights from its R&D event held on 19 August 2025. The event featured presentations from Alligator's management and scientific leadership, outlining Alligator's clinical progress, upcoming milestones, and strategic outlook. Key takeaways from the event include: Mitazalimab - Phase 3 readiness : Long-term follow-up data continue to demonstrate encouraging overall survival in metastatic pancreatic cancer, supporting the confirmed regulatory path and planned initiation of a Phase 3 trial. Scientific insights : New translational biomarker data further expand and strengthen the rationale for mitazalimab in pancreatic cancer and other solid tumors, underscored by myeloid and T-cell activation and their correlation with improved clinical outcomes. Trial completion and CMC status: The final, 30-month, data read-out from OPTIMIZE-1 is expected during Q3 2025. The trial will thereafter be finalized, with mitazalimab being provided to patients still on treatment, and sites with ongoing patients remain open under limited, risk-based monitoring; manufacturing of Phase 3 material has been successfully completed. Investigator-initiated trials (IITs) : Based on the significant investigator interest Alligator is engaged in a number of externally funded exploratory and Phase 2 clinical trials with mitazalimab across pancreatic, gastrointestinal and other solid tumors to expand mitazalimab's future clinical use. Individual trials are expected to start during H2 2025 and the first half of 2026. Pipeline updates : The HER2 antibody HLX22 (developed by Chinese Henlius) has entered a global Phase 3 trial in gastric cancers. Alligator expects to receive the next development milestone within 6-12 months, and estimates that its share of the future royalties will amount to SEK 150-400 million annually. Strategic outlook : With a reduced burn-rate, Alligator is well positioned to advance mitazalimab into registrational trials together with a partner, and in parallel explore additional development options for the asset. Together mitazalimab and HLX22 represent a significant financial upside for Alligator. Other pipeline assets and technologies represent additional future development and income opportunities. A replay of the event is available through >>this link<< . For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 12:15 p.m. CEST on 20 August 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit . Attachments Alligator Bioscience provides highlights from R&D event 2025 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire
